The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition

Main Article Content

Pedro Barata http://orcid.org/0000-0002-8890-2951
Moshe C Ornstein
Jorge A Garcia

Keywords

Advanced renal cell carcinoma, immunotherapy, mTOR inhibitors, PD-1/PD-L1, VEGF inhibitors

Abstract

Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.

Abstract 1394 | HTML Downloads 1215 PDF Downloads 376 XML Downloads 350